United Therapeutics Lawsuit Dismissal

United Therapeutics has faced a court decision dismissing its lawsuit against Liquidia. The ruling was made in a recent court proceeding.

Case Details

• The lawsuit filed by United Therapeutics against Liquidia has been dismissed by the court.
• The outcome of the case has no immediate impact on United Therapeutics’ stock price, which closed at $294.6 USD on the last trading day.

Stock Performance

United Therapeutics’ stock price has fluctuated within a range of $256.08 USD to $417.82 USD over the past year. Key valuation metrics include:

• Price to earnings ratio: 11.72
• Price to book ratio: 1.95

These ratios indicate a moderate valuation level for the company.